Novel avian paramyxovirus-based vaccine vectors expressing the Ebola virus glycoprotein elicit mucosal and humoral immune responses in guinea pigs.

Paramyxovirus vaccine vectors based on human parainfluenza virus type 3 (HPIV-3) and Newcastle disease virus (NDV) have been previously evaluated against Ebola virus (EBOV) challenge. Although both the viral vectored vaccines efficiently induce protective immunity， some concerns remain to be solved. Since HPIV-3 is a common human pathogen， the human population has pre-existing immunity to HPIV-3， which may restrict the replication of the vaccine vector. For NDV， mesogenic (intermediate virulent) strain used in previous studies is currently classified as a Select Agent in the United States， thus making it unsuitable to be used as a vaccine vector. To overcome these concerns， we have developed a modified NDV vector based on a mesogenic NDV strain， in which the ectodomains of envelope glycoproteins were replaced with the corresponding ectodomains from avian paramyxovirus serotype 3 (APMV-3). The modified NDV vector was highly attenuated in chickens and was able to express the EBOV glycoprotein (GP) gene at high level. In addition， the recombinant APMV-3 was also evaluated as a vaccine vector to express the EBOV GP gene. Guinea pigs immunized with these two vector vaccines developed high levels of neutralizing GP-specific IgG and IgA antibodies.